187 related articles for article (PubMed ID: 32042081)
41. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
42. Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy.
Vicente EP; Cuellar-García C; Martinez M; Soler A; Mora A; Bosch R; Brunet S; Briones J; García I; Esquirol A; Granell M; Saavedra S; Nomdedeu J; Sierra J; Martino R; Moreno C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):737-742. PubMed ID: 30017595
[TBL] [Abstract][Full Text] [Related]
43. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
[TBL] [Abstract][Full Text] [Related]
44. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
[TBL] [Abstract][Full Text] [Related]
45. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.
Hallek M; Langenmayer I; Nerl C; Knauf W; Dietzfelbinger H; Adorf D; Ostwald M; Busch R; Kuhn-Hallek I; Thiel E; Emmerich B
Blood; 1999 Mar; 93(5):1732-7. PubMed ID: 10029603
[TBL] [Abstract][Full Text] [Related]
46. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
49. Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia.
Alshemmari SH; Almazyad M; Alsarraf A; Kunhikrishnan A; Isaac AM; Kaempf A
Hematol Oncol Stem Cell Ther; 2024 Mar; 17(2):137-145. PubMed ID: 38560969
[TBL] [Abstract][Full Text] [Related]
50. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.
Del Giudice I; Mauro FR; De Propris MS; Santangelo S; Marinelli M; Peragine N; Di Maio V; Nanni M; Barzotti R; Mancini F; Armiento D; Paoloni F; Guarini A; Foà R
Haematologica; 2011 Apr; 96(4):626-30. PubMed ID: 21193417
[TBL] [Abstract][Full Text] [Related]
51. [Survival analysis of 118 chronic lymphocytic leukemia patients with abnormal TP53 gene in the era of traditional immunochemotherapy].
Li XT; Zhu HY; Wang L; Xia Y; Liang JH; Wu JZ; Wu W; Cao L; Fan L; Xu W; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):378-383. PubMed ID: 31207701
[No Abstract] [Full Text] [Related]
52. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Lucas DM; Ruppert AS; Lozanski G; Dewald GW; Lozanski A; Claus R; Plass C; Flinn IW; Neuberg DS; Paietta EM; Bennett JM; Jelinek DF; Gribben JG; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS; Byrd JC; Grever MR
Leuk Lymphoma; 2015; 56(11):3031-7. PubMed ID: 25721902
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Factors for Chronic Lymphocytic Leukemia.
Chen C; Puvvada S
Curr Hematol Malig Rep; 2016 Feb; 11(1):37-42. PubMed ID: 26748932
[TBL] [Abstract][Full Text] [Related]
54. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
Van Dyke DL; Werner L; Rassenti LZ; Neuberg D; Ghia E; Heerema NA; Dal Cin P; Dell Aquila M; Sreekantaiah C; Greaves AW; Kipps TJ; Kay NE
Br J Haematol; 2016 Apr; 173(1):105-13. PubMed ID: 26848054
[TBL] [Abstract][Full Text] [Related]
55. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.
Tobin G; Thunberg U; Laurell A; Karlsson K; Aleskog A; Willander K; Söderberg O; Merup M; Vilpo J; Hultdin M; Sundström C; Roos G; Rosenquist R
Haematologica; 2005 Apr; 90(4):465-9. PubMed ID: 15820941
[TBL] [Abstract][Full Text] [Related]
56. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival.
Molica S; Levato D; Dattilo A
Haematologica; 1999 Dec; 84(12):1094-9. PubMed ID: 10586211
[TBL] [Abstract][Full Text] [Related]
57. A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia.
Tecchio C; Nichele I; Mosna F; Zampieri F; Leso A; Al-Khaffaf A; Veneri D; Andreini A; Pizzolo G; Ambrosetti A
Eur J Haematol; 2011 Sep; 87(3):228-34. PubMed ID: 21595749
[TBL] [Abstract][Full Text] [Related]
58. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
59. A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.
Hernández JÁ; Hernández-Sánchez M; Rodríguez-Vicente AE; Grossmann V; Collado R; Heras C; Puiggros A; Martín AÁ; Puig N; Benito R; Robledo C; Delgado J; González T; Queizán JA; Galende J; de la Fuente I; Martín-Núñez G; Alonso JM; Abrisqueta P; Luño E; Marugán I; González-Gascón I; Bosch F; Kohlmann A; González M; Espinet B; Hernández-Rivas JM;
PLoS One; 2015; 10(11):e0143073. PubMed ID: 26630574
[TBL] [Abstract][Full Text] [Related]
60. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
